UNH Q2 Crushes Estimates, Raises Outlook as Medical Costs Drop and AI Boosts Efficiency
UNH sits 82% above its 52-week low of $234.6 on elevated volume (1.8× avg).
Summary
UnitedHealth delivered a massive Q2 beat with adjusted EPS of $6.38 versus the $4.90 consensus, driven by a lower medical-cost ratio of 86.7%. The company raised its full-year 2026 adjusted EPS guidance to $19.50–$20.00 and revenue to over $439B, while doubling its buyback target to $5B. Medicare Advantage membership is expected to decline by about 1.1 million as the company prioritizes margin over growth. AI tools added 200,000 patient-facing hours and slashed clinician burnout by 90%, signaling operational leverage. This follows the initial Q2 report yesterday and adds granularity on cost trends and the Baird upgrade to Neutral. The sharp guidance raise and cost control suggest the turnaround is gaining traction.
At the time of this announcement, UNH was trading at $426.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $384.5B. The 52-week trading range was $234.60 to $461.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.